Filter posts

#TBT: Debunking Some Common Myths on Patent Protections

The Subcommittee on Consumer Protection and Commerce of the Committee on Energy and Commerce is …

Discussing a “Patient-Centered” Approach at BIO 2019

Placing patients at the center of everything the biotech industry stands for is a personal …

Why Concerns About a “Break Down” in Drug Pricing Are Misplaced

Just moments after it was announced the FDA had approved a new treatment for spinal …

The Empty Promise of “Safe” Drug Importation

For years, BIO has been urging both state and federal policymakers to adopt responsible solutions …

I-MAK’s Distorted View of the U.S. Patent System

In an opinion piece published at CNBC.com, Tahir Amin — co-founder of I-MAK — blames …

Insurers Shift Costs and Facts

As health insurance companies begin setting rates for 2019, many consumers are once again faced …

ICER Comes Under Renewed Scrutiny

As we enter a new and exciting era of medicine, there is an important question …

#BIOCEO18: A Bright Future

“A transformative year in medicine.” That’s how BIO President and CEO Jim Greenwood recently described …

Here We Go Again (But In a Good Way)

“We achieved the lowest drug trend since we began measuring drug trend data in 1993.” …

A Flawed Bill That Would Harm Seniors

The Medicare prescription drug program has been a remarkable success for both seniors and taxpayers, …